Atish D Choudhury, Lillian Werner, Edoardo Francini, Xiao X Wei, Gavin Ha, Samuel S Freeman, Justin Rhoades, Sarah C Reed, Gregory Gydush, Denisse Rotem, Christopher Lo, Mary-Ellen Taplin, Lauren C Harshman, Zhenwei Zhang, Edward P O'Connor, Daniel G Stover, Heather A Parsons, Gad Getz, Matthew Meyerson, J Christopher Love, William C Hahn, Viktor A Adalsteinsson
BACKGROUND: Tumor content in circulating cell-free DNA (cfDNA) is a promising biomarker, but longitudinal dynamics of tumor-derived and non-tumor-derived cfDNA through multiple courses of therapy have not been well described. METHODS: CfDNA from 663 plasma samples from 140 patients with castration-resistant prostate cancer (CRPC) was subject to sparse whole genome sequencing. Tumor fraction (TFx) estimated using the computational tool ichorCNA was correlated with clinical features and responses to therapy...
November 2, 2018: JCI Insight